Kinetics and biodistribution in relation to tumour detection with 111 In labelled OV-TL 3 F(ab,)2 in patients with ovarian cancer

SUMMARYThe biological behaviour of In-labelled OV-TL 3 F(ab')2 was studied in 22 patients with suspected ovarian cancer. After i.v. injection with 140 MBq In-OV-TL 3 F(ab')2 (1 mg) blood samples were taken up to 96 h and urine and faeces were collected throughout the whole study. At surgery; 5 to 7 days post-injection, primary and metastatic tumour tissues, as well as fragments of several normal tissues, were removed and In uptake was measured. Blood activity disappeared with half-life values of 6.1 |Mp 1.1 and 17.9 |Mp 6.5 h. Within 96 h excretion in urine and faeces was 16.1 |Mp 2.0% i.d. (mean |Mp S.D.) and 3.1 |Mp 1.9% i.d., respectively. Mean tissue uptake, expressed as % i.d. kg was 3.9 |Mp 1.0 for primary tumour, 11.5 |Mp 5.0 for liver and 0.4 |Mp 0.1 for several normal background tissues. Higher tumour uptake correlated with a higher detection rate at immunoscintigraphy. However, no strict correlation was found between the amount of tumour uptake and the expression of the monoclonal antibody defined OA3 antigen. Quantitation of organ activity, using region of interest analysis, resulted in mean peak organ activities for the liver of 16% i.d., spleen 9% i.d. and kidney 4% i.d. Distribution data indicate that besides specific antibody-antigen interaction several other mechanisms play a role in uptake in tumour and other tissues.